Literature DB >> 27233613

miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A.

Xiao Chang1, Haiping Zhang1, Shi Lian2, Wei Zhu3.   

Abstract

As an oncogene, aurora kinase A (AURKA) is overexpressed in various types of human cancers. However, the expression and roles of AURKA in malignant melanoma are largely unknown. In this study, a miR-137-AURKA axis was revealed to regulate melanoma growth. We found a significant increase in levels of AURKA in melanoma. Both genetic knockdown and pharmacologic inhibition of AURKA decreased tumor cell growth in vitro and in vivo. Further found that miR-137 reduced AURKA expression through interaction with its 3' untranslated region (3'UTR) and that miR-137 was negatively correlated with AURKA expression in melanoma specimens. Overexpression of miR-137 decreased cell proliferation and colony formation in vitro. Notably, re-expression of AURKA significantly rescued miR-137-mediated suppression of cell growth and clonality. In summary, these results reveal that miR-137 functions as a tumor suppressor by targeting AURKA, providing new insights into investigation of therapeutic strategies against malignant melanoma.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aurora kinase A; Cell growth; Malignant melanoma; miR-137

Mesh:

Substances:

Year:  2016        PMID: 27233613     DOI: 10.1016/j.bbrc.2016.05.090

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  FOXK1 promotes cell growth through activating wnt/β-catenin pathway and emerges as a novel target of miR-137 in glioma.

Authors:  Zhen-Gang Ji; Hai-Tao Jiang; Pei-Song Zhang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

2.  Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy.

Authors:  Yuan-Yuan Shang; Nan Yu; Li Xia; Ying-Yao Yu; Chun-Mei Ma; Ya-Ning Jiao; Yun-Feng Li; Yuan Wang; Jie Dang; Weichao Li
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

Review 3.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Identification of key candidate genes involved in melanoma metastasis.

Authors:  Jia Chen; Fei Wu; Yu Shi; Degang Yang; Mingyuan Xu; Yongxian Lai; Yeqiang Liu
Journal:  Mol Med Rep       Date:  2019-05-30       Impact factor: 2.952

5.  Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development.

Authors:  Mitzli X Velasco; Adam Kosti; Gabriela D A Guardia; Marcia C Santos; Allison Tegge; Mei Qiao; Bruna R S Correa; Greco Hernández; Erzsebet Kokovay; Pedro A F Galante; Luiz O F Penalva
Journal:  RNA       Date:  2019-04-19       Impact factor: 4.942

Review 6.  Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis.

Authors:  Olga S Cherepakhin; Zsolt B Argenyi; Ata S Moshiri
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.